中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

28 records (took 0.014 seconds)

    ACTIVITIES OF MULTIPLE CANCER-RELATED PATHWAYS ARE ASSOCIATED WITH BRAF MUTATION AND PREDICT THE RESISTANCE TO BRAF/MEK INHIBITORS IN MELANOMA CELLS
    1.
    发明申请
    ACTIVITIES OF MULTIPLE CANCER-RELATED PATHWAYS ARE ASSOCIATED WITH BRAF MUTATION AND PREDICT THE RESISTANCE TO BRAF/MEK INHIBITORS IN MELANOMA CELLS 审中-公开
    多发性癌相关途径的活动与BRAF突变相关，并预测了对BRAF / MEK抑制剂对血清细胞的抵抗力

    公开(公告)号：WO2015039107A1

    公开(公告)日：2015-03-19

    申请号：PCT/US2014/055884

    申请日：2014-09-16

    Applicant: THE JOHNS HOPKINS UNIVERSITY

    Inventor： XING, Michael Mingzhao ,  LIU, Dingxie

    IPC: C12Q1/68 ,  G01N33/53

    CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5743 ,  G01N2333/525 ,  G01N2333/56 ,  G01N2333/57 ,  G01N2333/71 ,  G01N2800/52

    Abstract: The present inventors have identified specific oncogenic pathways preferentially activated in BRAF-mutated-melanoma cells and a pathway pattern that predicts resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors, providing novel clinical implications for melanoma therapy. In one embodiment, a method comprises (a) testing a sample oiBRAF- mutated melanoma cells isolated from a patient and measuring the expression levels of genes expressed in the following oncogenic pathways: TNFa, EGFR, IFNa, hypoxia, IFNy, STAT3 and Myc; (b) calculating a 7-pathway activation pattern based on the measured expression levels of step (a); and (c) identifying the patient's resistance level to BRAF/MEK inhibitor treatment based on comparison of the calculated 7-pathway activation pattern to a reference.

    Abstract translation: 本发明人鉴定了BRAF-突变黑素瘤细胞中优先活化的特异性致癌途径和预测BRAF-突变黑素瘤对BRAF / MEK抑制剂抗性的途径模式，为黑素瘤治疗提供了新的临床意义。 在一个实施方案中，方法包括（a）测试从患者分离的样品oBRBR突变的黑素瘤细胞，并测量在以下致癌途径中表达的基因的表达水平：TNFα，EGFR，IFNα，缺氧，IFNγ，STAT3和Myc; （b）基于所测量的步骤（a）的表达水平计算7-途径激活模式; 和（c）基于计算出的7通路激活模式与参照的比较，确定患者对BRAF / MEK抑制剂治疗的耐药水平。

    DETERMINING RESISTANCE TO TREATMENT FOR HEPATITIS C VIRUS
    4.
    发明申请
    DETERMINING RESISTANCE TO TREATMENT FOR HEPATITIS C VIRUS 审中-公开
    决定抗病毒治疗乙型肝炎病毒

    公开(公告)号：WO00019209A1

    公开(公告)日：2000-04-06

    申请号：PCT/US1999/022374

    申请日：1999-09-28

    IPC: G01N33/576 ,  G01N33/68

    CPC classification number: G01N33/5767 ,  G01N33/6869 ,  G01N2333/18 ,  G01N2333/54 ,  G01N2333/56 ,  G01N2800/52

    Abstract: Methods for identifying hepatitis C virus (HCV)-infected subjects responsive to treatment for HCV infection or unlikely to respond to treatment for HCV infection are described. The level of Th2 cytokines in the subject during treatment serves as an indicator of whether the subject is likely to respond to treatment for HCV, e.g., interferon treatment. An elevated level of at least one Th2 cytokine during treatment indicates that an HCV-infected subject is unlikely to respond to a treatment for HCV. A decreased level of at least one TH2 cytokine indicates that an HCV-infected subject is responsive to a treatment for HCV. In a preferred embodiment, IL-10 levels are detected to identify subjects responsive to or unlikely to respond to interferon treatment.

    Abstract translation: 描述了鉴定丙型肝炎病毒（HCV）感染的受试者对HCV感染的治疗或对HCV感染的治疗不能应答的方法。 治疗期间受试者中Th2细胞因子的水平用作对象是否可能对HCV治疗有反应的指标，例如干扰素治疗。 在治疗期间升高的至少一种Th2细胞因子水平表明HCV感染的受试者不太可能对HCV的治疗作出反应。 至少一种TH2细胞因子的降低水平表明HCV感染的受试者对HCV的治疗有反应。 在优选的实施方案中，检测IL-10水平以鉴定对干扰素治疗有反应或不可能响应的受试者。

    IDENTIFICATION OF SUBJECTS AT RISK OF DEVELOPING VENTILATOR-ASSOCIATED PNEUMONIA
    6.
    发明申请
    IDENTIFICATION OF SUBJECTS AT RISK OF DEVELOPING VENTILATOR-ASSOCIATED PNEUMONIA 审中-公开
    有可能发展为呼吸机相关肺炎的对象的识别

    公开(公告)号：WO2017158142A1

    公开(公告)日：2017-09-21

    申请号：PCT/EP2017/056346

    申请日：2017-03-17

    Applicant: UNIVERSITEIT ANTWERPEN

    Inventor： KUMAR-SINGH, Samir ,  BIELEN, Kenny ,  GOOSENS, Herman ,  JORENS, Philippe ,  MALTHOTRA-KUMAR, Surbhi ,  'S JONGERS, Bart

    IPC: G01N33/68

    CPC classification number: G01N33/6869 ,  G01N2333/56 ,  G01N2800/12 ,  G01N2800/50

    Abstract: The present invention relates to the field of ventilator-associated pneumonia, caused by mechanical ventilation of a subject. In particular, it relates to the identification of subjects at risk of developing ventilator-associated pneumonia upon mechanical ventilation of said subject; wherein the identification of said subjects being at risk of developing VAP is based on the determination of one or more interleukins. The present invention also relates to the use of interleukin-reducing compounds for reducing the severity and/or progression of ventilator associated pneumonia in a subject being mechanically ventilated.

    Abstract translation: 呼吸机相关肺炎的领域本发明涉及由对象的机械通气引起的呼吸机相关肺炎的领域。 特别涉及识别在所述受试者机械通气时有风险产生呼吸机相关性肺炎的受试者; 其中所述受试者处于发生VAP的风险中的鉴定基于一种或多种白细胞介素的确定。 本发明还涉及白细胞减少化合物用于降低机械通气的受试者中呼吸机相关肺炎的严重程度和/或进展的用途。

Patent Agency Ranking